KYOWA-KIRIN
11.12.2023 15:01:37 CET | Business Wire | Press release
Kyowa Kirin International (KKI), a wholly owned subsidiary of Kyowa Kirin Co. Ltd, today announced health-related quality of life (HRQL) findings from a post hoc analysis of the MAVORIC trial in patients with mycosis fungoides (MF) or Sézary syndrome (SS), two subtypes of cutaneous T-cell lymphoma (CTCL).
Researchers analysed baseline data collected prior to initiation of study treatment and found the symptoms of advanced MF/SS affected HRQL across all domains, with poorer HRQL associated with being younger in age, female, having moderate or severe itching, and impaired function as measured by the Eastern Cooperative Oncology Group performance status (ECOG PS).
“CTCL is a chronic, life-long condition. Understanding how symptoms impact an individual physically, emotionally as well as in their daily life is critical,” said Susan Thornton, Chief Executive Officer, Cutaneous Lymphoma Foundation and one of the study authors. “The data provide new insights into the burdens of living with CTCL, and the patient characteristics associated with a poorer quality of life - important factors to consider when developing a care plan for a patient.”
Cutaneous T-cell lymphoma is a rare form of non-Hodgkin’s lymphoma that most prominently affects the skin, presenting as patches, plaques, tumours or erythroderma (reddening of the skin), and may be associated with severe pruritus (itching). In advanced cases, the disease may spread to the lymph nodes, blood, and/or viscera.
To determine the impact of CTCL on HRQL, researchers analysed data collected at baseline from 372 MAVORIC trial participants using Skindex-29, which evaluates the effect of skin disease on HRQL; the ItchyQol, which is a pruritus-specific measure of HRQL; and the Functional Assessment of Cancer Therapy – General (FACT-G), which measures HRQL in people with cancer. The findings were analysed at the individual question level and scored according to instrument guidelines. Bivariate analysis (t-tests and ANOVA) was used to identify demographic and medical history variables that had a relationship with HRQL. LASSO (least absolute shrinkage and selection operator) regression analysis was used to identify factors that may drive poor HRQL.
Results show the symptoms of advanced MF/SS affected HRQL across all domains with worse scores seen in Symptoms for Skindex-29, Well-being for FACT-G and Functioning for ItchyQoL. In bivariate analysis, a worse total score across all three HRQL measures were related to being younger, female, having moderate or severe pruritis, ECOG performance status 1 or 2, and higher mSWAT (Modified Severity-Weighted Assessment Tool) scores. In multivariate analysis, worse HRQL was associated with being younger, female, moderate or severe pruritus and impaired function (as measured by ECOG PS). Researchers concluded that assessing a patient’s disease concerns may help guide treatment goals and therapeutic choice.
About MAVORIC
MAVORIC (Mogamulizumab anti-CCR4 Antibody Versus Comparator In CTCL) was an international, open label, Phase 3, randomised controlled trial that evaluated the safety and efficacy of Poteligeo® (mogamulizumab) versus vorinostat in patients with relapsed or refractory MF or SS (stage IB–IVB) previously treated with at least one systemic therapy. The study population (n=372) had a mean age of 63 years (SD 13.0). Fifty-five percent of patients had MF, 45% SS, and 77% had advanced disease (stage IIB–IV). The disease involved the skin in all patients and the blood and/or nodes in 66%. ECOG performance status was stage 0, 1, and 2 in 56%, 43%, and <1% of patients, respectively.
To view the full press release, click here.
KKI/INT/MOG/1002
Date of preparation: December 2023
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231211833501/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Don’t Let Europe’s Nicotine Black Market Go Unchecked16.11.2026 08:06:00 CET | Press release
Crime Stoppers International asks the public to report illegal vapes and nicotine pouches as organised crime cashes in across Europe. Launched on the UN day against transnational organised crime: the criminals selling black market vapes and nicotine pouches also traffic fake medicine, illicit drugs and weapons. On the UN International Day against Transnational Organised Crime, Crime Stoppers International (CSI) launched Don’t let it go unchecked, a campaign asking the public to help break Europe’s black market in vapes and nicotine pouches by reporting illegal sellers anonymously. This matters more than ever. Illegal vapes and nicotine pouches are flooding into Europe. The sellers don’t care how they’re made or who buys them, and don’t pay taxes. Nobody knows who's behind them, except the criminal networks cashing in. The illegal trade in nicotine products is funding the same criminal networks that traffic fake medicine, illicit drugs and weapons, and putting untested products into the
Sofinnova Partners Closes €725M Crossover II Fund16.11.2026 08:00:00 CET | Press release
Backing late-stage life sciences companies through to clinical development, global expansion and commercialization. Positions Sofinnova to support approximately 15 high-growth companies, primarily in Europe, with selective investments in the U.S. and other markets. Sofinnova Partners (“Sofinnova”), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced the final close of Sofinnova Crossover II at €725 million ($815 million USD). The fund exceeded its original target, reflecting growing confidence in Sofinnova’s strategy of backing late-stage life sciences companies with the potential to become global leaders. Sofinnova Crossover II will focus primarily on European clinical-stage biopharma and medtech companies seeking capital to advance toward commercialization. It will also invest in best-in-class companies in the United States and other international markets. Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, said
Ant International’s Alipay+ and The New York Liberty Celebrate Season of Sustainability Impact on Community, Environmental and Youth Empowerment16.11.2026 05:08:00 CET | Press release
The first-season partnership delivers tangible results: 219 trees planted, 650 pairs of shoes donated, and youth empowered through inaugural Math Hoops tournament Ant International’s Alipay+, a leading cross-border fintech services platform, and the WNBA’s New York Liberty, today announced the results of their joint sustainability initiatives for the season. Marking the first season of the multi-year collaboration, Alipay+ and the New York Liberty planted a total of 219 trees — one for every three-pointer made by the New York Liberty and Alipay+ in-game fan contestants during home games at Barclays Center this season. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261115082353/en/ Students celebrate during the inaugural Liberty NBA Math Hoops Regional Tournament. In addition to the on-court tree-planting pledge, the partners concluded their fan-driven Sneaker Drive, collecting 650 pairs of shoes to support environmental cons
VELOCIFERO Takes Action Against Counterfeiting in China13.11.2026 17:32:00 CET | Press release
White s.r.o., exclusive owner of the VELOCIFERO brand, takes action in China to protect its intellectual property rights. Initial measures in Chongqing and Taizhou have already resulted in the seizure of vehicles alleged to be counterfeit. VELOCIFERO is taking action against counterfeiting in China. White s.r.o., the exclusive owner of the VELOCIFERO brand and its related intellectual property rights, has launched decisive measures to protect its creative and industrial assets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261113797570/en/ Photo courtesy of White s.r.o. “Vehicle sealed in Chongqing as part of actions undertaken to protect VELOCIFERO’s intellectual property rights.” The matter originated in June 2026 when, according to the company’s complaint, computers were removed from the technical office of Taizhou Siweiluo, the company appointed to manufacture VELOCIFERO products. White s.r.o. subsequently became aware
LangChain Raises $300M to Enable Every Company to Own Their Intelligence13.11.2026 16:53:00 CET | Press release
CapitalG leads Series C funding round at a $3B valuation to advance LangChain's agent engineering platform LangChain today announced it has raised $300 million in new funding at a $3 billion valuation, bringing total funding to date to $460 million. The round was led by existing investor CapitalG, with significant participation from new investors GIC and DFJ Growth and existing investors IVP and Sapphire Ventures. LangChain is advancing its mission to help every company own its intelligence. As agents transform the economy, companies are building domain-specific agents differentiated by their knowledge, data, and user experience. These agents will power new products and transform internal company operations, creating lasting competitive advantages for the companies that control them. "Agents are going to transform how companies operate and the products they deliver. The companies that control these systems will build lasting competitive advantages," said Harrison Chase, Co-Founder and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
